Literature DB >> 32900727

Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement.

Jesse Mooneyham1, Cesar Gentille2, Andrea Barbieri3, Shilpan Shah4.   

Abstract

A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m2 The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (drugs and medicines); malignant and benign haematology; malignant disease and immunosuppression; neurooncology; neurosurgery

Mesh:

Substances:

Year:  2020        PMID: 32900727      PMCID: PMC7478030          DOI: 10.1136/bcr-2020-235412

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Lymphomatoid granulomatosis.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

2.  Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement.

Authors:  J H Kappen; H C T van Zaanen; S M Snelder; A J P van Tilburg; A Rudolphus
Journal:  BMJ Case Rep       Date:  2017-02-06

Review 3.  Lymphomatoid granulomatosis: insights gained over 4 decades.

Authors:  Anna-Luise A Katzenstein; Erika Doxtader; Sonia Narendra
Journal:  Am J Surg Pathol       Date:  2010-12       Impact factor: 6.394

4.  Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations.

Authors:  Joo Y Song; Stefania Pittaluga; Kieron Dunleavy; Nicole Grant; Therese White; Liuyan Jiang; Theresa Davies-Hill; Mark Raffeld; Wyndham H Wilson; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

5.  Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature.

Authors:  Julio C Chavez; Jose Sandoval-Sus; Pedro Horna; Samir Dalia; Celeste Bello; Paul Chevernick; Eduardo M Sotomayor; Lubomir Sokol; Bijal Shah
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

6.  Lymphomatoid granulomatosis involving central nervous system successfully treated with rituximab alone.

Authors:  Hiroyuki Ishiura; Masato Morikawa; Masashi Hamada; Takuro Watanabe; Shinichi Kako; Shigeru Chiba; Toru Motokura; Akira Hangaishi; Junji Shibahara; Masaaki Akahane; Jun Goto; Shin Kwak; Mineo Kurokawa; Shoji Tsuji
Journal:  Arch Neurol       Date:  2008-05

7.  Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases.

Authors:  Joong-Yub Kim; Kyeong Cheon Jung; Sung-Hye Park; Ji-Young Choe; Ji Eun Kim
Journal:  Neuropathology       Date:  2018-04-10       Impact factor: 1.906

8.  Successful treatment of systemic and central nervous system lymphomatoid granulomatosis with rituximab.

Authors:  A Zaidi; B Kampalath; W L Peltier; D H Vesole
Journal:  Leuk Lymphoma       Date:  2004-04

9.  Lymphomatoid granulomatosis of central nervous system and lung driven by epstein barr virus proliferation: successful treatment with rituximab-containing chemotherapy.

Authors:  Ruben Fernandez-Alvarez; Me Gonzalez; Almudena Fernandez; Ap Gonzalez-Rodriguez; Jm Sancho; Francisco Dominguez; Carmen Fernandez
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-16       Impact factor: 2.576

10.  Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report.

Authors:  Cecilia T Costiniuk; Jason Karamchandani; Ali Bessissow; Jean-Pierre Routy; Jason Szabo; Charles Frenette
Journal:  BMC Infect Dis       Date:  2018-05-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.